The treatment of pediatric chronic myelogenous leukemia in the imatinib era

Korean Journal of Pediatrics

Volumn 54, Issue 3, 2011, Pages 110-115

  Lee, Jae Wook ^a   Chung, Nack Gyun ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Children; Chronic myelogenous leukemia; Imatinib; Transplantation; Treatment; Tyrosine kinase inhibitors

Indexed keywords

EID: 79958069450     PISSN: 17381061     EISSN: 20927258     Source Type: Journal    
DOI: 10.3345/kjp.2011.54.3.110     Document Type: Article

References (39)

1. Altman AJ. Chronic leukemias of childhood. Pediatr Clin North Am 1988;35:765-87.
2. Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 1960;132:1497.
3. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia. Nature 1973;243:290-3.
4. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
5. Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 2005;116:140-3.
6. Vardiman JW, Melo JV, Baccarani M, Thiele J. Chronic myelogenous leukemia, BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele, J., Vardiman, J.W, editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon:IARC, 2008:32-7.
7. Suttorp M, Yaniv I, Schultz KR. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant 2011;17(1Suppl): 115 S-22 S.
8. Apperley J. CML in pregnancy and childhood. Best Pract Res Clin Haematol 2009;22:455-74.
9. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27:6041-51.
10. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al; The German CML Study Group. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 1993;82:398-407.
11. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al; French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-9.
12. Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukaemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 1999;17:284-92.
13. Arthur CK, Ma DD. Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol 1993;89 Suppl 1:S15-21.
14. Millot F, Guilhot J, Nelken B, Leblanc T, Leverger G, Bernard F, et al. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia. Pediatr Blood Cancer 2006;47:555-9.
15. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
16. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
17. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
18. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 2004;104:2655-60.
19. Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stemcell transplantation. Hematology Am Soc Hematol Educ Program 2010;2010:368-76.
20. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-19.
21. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Chronic myelogenous leukemia. Available from: www.nccn.org/index.asp. Accessed February, 2011.]
22. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplant 2008;42 Suppl 2:S40-6.
23. Zwaan CM, Rizzari C, van der Velden VHJ, Beverloo B, den Boer ML, Baruchel A, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: interim results of the CA180-018 phase I study from the ITCC consortium. Blood 2008;112:3241a 24).
24. Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Bekassy AN, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006;20:187-92.
25. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, et al; a Children's Oncology Group study. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors. Pediatr Blood Cancer 2008;50:254-8.
26. Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:409-29.
27. Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, et al. Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia (CML) in early chronic phase (CP): results of the French national phase IV trial. Blood 2009;114:863a.
28. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-13.
29. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol 2009;89:251-2.
30. Vandyke K, Dewar AL, Fitter S, Menicanin D, To LB, Hughes TP, et al. Imatinib mesylate causes growth plate closure in vivo. Leukemia 2009;23:2155-9.
31. Mariani S, Giona F, Basciani S, Brama M, Gnessi L. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008;372:111-2.
32. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program 2005:183-7.
33. Suttorp M, Claviez A, Bader P, Peters C, Gadner H, Ebell W, et al. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. Klin Padiatr 2009;221:351-7.
34. Millot F, Esperou H, Bordigoni P, Dalle JH, Michallet M, Michel G, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2003;32:993-9.
35. Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003;102:1224-31.
36. Horn B, Baxter-Lowe LA, Englert L, McMillan A, Quinn M, Desantes K, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 2006;37:263-9.
37. Muramatsu H, Kojima S, Yoshimi A, Atsuta Y, Kato K, Nagatoshi Y, et al. Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Biol Blood Marrow Transplant 2010;16:231-8.
38. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35.
39. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984;1:665-8.